Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

International Nursing Organizations II

International Nursing Organizations II

The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Artificial intelligence and medical futility.

BMC medical informatics and decision making·2026

Same author

Guiding Policymakers Toward Better AI Ethics Integration in Healthcare Regulation-Lessons from Singapore.

Journal of clinical medicine·2026

Same author

Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026

Same author

A Licensure Framework for Autonomous Clinical AI.

JAMA·2026

Same author

A survey of public attitudes toward secondary research governance oversight: Evidence from Singapore's TRUST platform.

International journal of population data science·2026

Same author

A randomized control trial of re-designed and shorter research informed consent forms to improve comprehension.

Clinical trials (London, England)·2026

Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026

Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026

Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026

Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026

Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026

Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 23, 2025

Analysis of Iophenoxic Acid Analogues in Small Indian Mongoose Herpestes Auropunctatus Sera for Use as an Oral Rabies Vaccination Biological Marker

Analysis of Iophenoxic Acid Analogues in Small Indian Mongoose Herpestes Auropunctatus Sera for Use as an Oral Rabies Vaccination Biological Marker

Published on: May 31, 2019

Equitable global allocation of monkeypox vaccines.

G Owen Schaefer¹, Ezekiel J Emanuel², Caesar A Atuire³

¹Centre for Biomedical Ethics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

|July 17, 2023

Summary

This summary is machine-generated.

Equitable monkeypox vaccine allocation is crucial. The Fair Priority Model prioritizes post-exposure prophylaxis (PEPV) and historically endemic countries to prevent harm and address global health disparities.

Keywords:

Fair priority model Global Health Monkeypox Monkeypox vaccines Mpox PEPV PreP Vaccine allocation

More Related Videos

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Jul 23, 2025

Analysis of Iophenoxic Acid Analogues in Small Indian Mongoose Herpestes Auropunctatus Sera for Use as an Oral Rabies Vaccination Biological Marker

Analysis of Iophenoxic Acid Analogues in Small Indian Mongoose Herpestes Auropunctatus Sera for Use as an Oral Rabies Vaccination Biological Marker

Published on: May 31, 2019

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses

Published on: August 31, 2014

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Area of Science:

Global Health
Epidemiology
Vaccine Equity

Background:

The global spread of monkeypox necessitates effective vaccine strategies.
Historically endemic countries face disproportionately high case-fatality rates and limited vaccine access.
Current vaccine distribution models exacerbate existing global health inequities.

Purpose of the Study:

To propose an equitable framework for global monkeypox vaccine allocation.
To advocate for prioritizing vulnerable populations and historically endemic regions.
To ensure fair access to vaccines for both post-exposure (PEPV) and pre-exposure (PrEP) prophylaxis.

Main Methods:

Application of the Fair Priority Model for vaccine allocation.
Prioritization of harm reduction through post-exposure prophylaxis (PEPV).
Sequential allocation prioritizing historically endemic countries for both PEPV and pre-exposure prophylaxis (PrEP).

Main Results:

The Fair Priority Model offers a just framework for distributing scarce monkeypox vaccines.
Prioritizing PEPV ensures immediate harm mitigation for at-risk populations.
Historically endemic nations should receive preferential access to vaccines to address existing disadvantages.

Conclusions:

Equitable global vaccine allocation is essential to mitigate the impact of monkeypox.
The Fair Priority Model provides a robust ethical framework for vaccine distribution.
Addressing the needs of historically endemic countries is paramount for global health security and justice.